NewLimit Secures $435 Million for Upcoming Clinical Trial of Liver Medicine
NewLimit, a longevity-focused startup, has successfully raised $435 million in funding, which will support its first clinical trial targeting liver medicine.
Editorial Staff
1 min read
Updated 7 days ago
NewLimit, a startup dedicated to longevity research, has announced a significant funding milestone of $435 million.
This funding will be directed towards launching the company's first clinical trial, which will focus on a liver medicine.
The substantial investment highlights the growing interest and potential in the field of longevity and medical advancements.